ACUTE MYELOID LEUKEMIA

This early-stage study is testing the safety of combining two drugs, venetoclax and decitabine, for adults with high-risk acute myeloid leukemia (AML). The main goal is to find the highest dose patients can tolerate without severe side effects. It is for patients whose cancer has…

This program provides access to Orca-T cell therapy for patients with blood cancers when the standard commercial product doesn't meet quality specifications. It's designed for patients who were already scheduled to receive Orca-T but whose manufactured product didn't pass all rel…

This early-stage study tests whether modifying a patient's own leukemia cells to produce an immune-stimulating protein (IL-12) and returning them to the body is safe. It involves 9 adults with high-risk acute myeloid leukemia who cannot receive bone marrow transplants. Researcher…

This is the first study in people to test a new oral pill called NTX-301. It aims to see if the drug is safe and can help control advanced forms of leukemia and related blood cancers that have come back or stopped responding to other treatments. The study will enroll about 22 adu…

This study is testing whether taking the drug ruxolitinib after a stem cell transplant can help prevent cancer from returning in older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The trial involves 64 participants aged 60-80 who have achieved rem…

This study is testing whether specially grown cord blood stem cells can help patients with high-risk blood cancers recover their immune systems faster after a transplant. Participants receive a transplant using these expanded stem cells after strong chemotherapy. Researchers are …

This early-stage study is testing a new, more targeted form of radiation given before a stem cell transplant for patients with acute myeloid leukemia (AML) in remission. The goal is to see if focusing radiation only on the bone marrow and lymph nodes, instead of the whole body, i…

This study allows patients with certain blood cancers who were benefiting from ASTX727 treatment in previous trials to continue receiving the medication. The main goal is to collect long-term safety information about the drug. Participants will receive the same dose they were tak…

This study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, to treat older adults with a type of blood cancer called acute myeloid leukemia (AML). The goal was to see if this combination was safe and effective enough to put patients into remission and war…

This early-stage study is testing a new combination of three drugs—navtemadlin, decitabine, and venetoclax—for adults with acute myeloid leukemia (AML) that has returned, is resistant to treatment, or is newly diagnosed in patients who cannot tolerate intensive chemotherapy. The …

This early-stage study is testing whether two drugs—entrectinib and ASTX727—can be safely combined to treat acute myeloid leukemia (AML) that has returned or resisted treatment and has a specific genetic change (TP53 mutation). The trial involves about 13 adults and aims to find …

This study is testing whether adding two drugs, venetoclax and azacitidine, after a stem cell transplant can help prevent high-risk leukemia from returning. It is for adults aged 18-75 with certain types of acute leukemia who have already had a transplant. The goal is to see if t…

This early-stage study is testing a new drug called DR-18 for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer has come back or persisted after a stem cell transplant. The main goals are to find a safe dose and see what side effects it cau…

This study is testing if using a lower dose of a standard drug (cyclophosphamide) given after a stem cell transplant can reduce serious infections in the first 100 days. The trial aims to see if this lower dose is just as good at preventing graft-versus-host disease, a common and…

This early-stage trial is testing whether a combination of two immune-based treatments is safe for patients whose blood cancer has returned after a stem cell transplant. The study involves 25 adults with conditions like acute myeloid leukemia or myelodysplastic syndromes. Researc…

This study is observing how well the drug venetoclax works for people with acute myeloid leukemia (AML) during their normal medical care in Israel. It will follow 100 patients to see how long they live, if their cancer goes into remission, and how their quality of life changes. T…

This study is testing if adding a drug called pomalidomide to standard chemotherapy works better for adults newly diagnosed with a specific, harder-to-treat type of acute myeloid leukemia (AML). About 50 participants will be randomly assigned to receive either the standard chemo …

This early-stage study is testing a new drug called bexmarilimab, which works with the immune system, in combination with standard cancer treatments. It aims to find a safe dose and see if the combination helps adults with advanced forms of blood cancers like myelodysplastic synd…

This study is testing whether two drugs, ASTX727 and venetoclax, work well together and are safe for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. Researchers want to see if the drugs interact safely in the body and whe…

This early-stage trial tests whether infusing specially prepared immune cells from a transplant donor can prevent acute myeloid leukemia from returning in high-risk patients. Researchers will determine the safest dose and see if this approach improves survival without causing har…

This early-stage study is testing whether adding the drug venetoclax to standard chemotherapy is safe for adults newly diagnosed with acute myeloid leukemia (AML). The main goal is to find the highest dose of venetoclax that can be given safely alongside chemotherapy. Researchers…

This study tests whether giving patients a special type of 'memory-like' immune cell after a half-matched bone marrow transplant can help keep leukemia from coming back. It's for adults with high-risk acute myeloid leukemia that hasn't responded well to standard treatments. Resea…

This study is testing whether adding a new drug called uproleselan to standard chemotherapy works better for treating older adults with acute myeloid leukemia (AML). The goal is to see if the combination helps patients live longer and keeps the cancer from coming back. Researcher…

This study is testing if adding an immunotherapy drug (pembrolizumab) to a standard two-drug combination works better for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if the three-drug combo helps more p…

This trial is comparing a new, engineered cell transplant called Orca-T against the standard transplant for people with advanced blood cancers like leukemia. The goal is to see if Orca-T can better control the cancer while reducing a serious complication called graft-versus-host …

This study is testing whether combining three different cancer drugs can better control two aggressive types of blood cancer: Philadelphia chromosome-positive acute myeloid leukemia (AML) and advanced chronic myeloid leukemia (CML). The trial will enroll about 20 adults with thes…

This study is testing a combination of three drugs—azacitidine, venetoclax, and pevonedistat—for adults newly diagnosed with certain high-risk blood cancers. These include acute myeloid leukemia (AML) that developed from other blood disorders or prior cancer treatment, as well as…

This study is testing whether a combination of three drugs—chidamide, azacitidine, and the HAG regimen—can help control acute myeloid leukemia (AML) in adults when the cancer has come back or hasn't responded to previous treatments. The main goal is to see how well this combinati…

This study is testing whether a two-drug combination (azacitidine and venetoclax) can help keep acute myeloid leukemia (AML) from returning in patients who have achieved remission. The trial will enroll 50 adults with AML who are in remission but are not immediate candidates for …

This study is testing whether adding a drug called selinexor to standard chemotherapy works better for children with a specific, high-risk type of acute myeloid leukemia (AML) linked to a gene called NUP98. The goal is to see if this combination helps more children achieve remiss…

This is an early safety study testing a new drug called CRD3874-SI in adults with acute myeloid leukemia that has returned or not responded to other treatments. The drug is designed to activate a protein in the body called STING, which may help the immune system find and kill can…

This early-stage study is testing a new type of cell therapy for acute myeloid leukemia (AML) that has returned or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better recognize and attack the leukemia cells, an…

This study aims to understand how well the approved drug venetoclax works in real-world settings for adults with acute myeloid leukemia (AML) who are too old or frail for standard intensive chemotherapy. It will follow about 200 patients across Canada for three years, collecting …

This is an early, small study to find a safe and active dose of a new oral drug called tomivosertib for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. Up to 15 participants will take the pill daily in 28-day cycles while doctors c…

This study allows patients who benefited from previous clinical trials of ruxolitinib (alone or with panobinostat) to continue receiving their treatment while researchers monitor long-term safety. The study includes 279 patients with various blood conditions like myelofibrosis an…

This study is testing whether a new drug combination (venetoclax + CACAG) works better and is safer than the current standard chemotherapy ('3+7' regimen) for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). It will involve 160 participants who…

This early-stage study aims to find the safest and most effective dose of a targeted radiation treatment, given with chemotherapy, to prepare patients for a donor stem cell transplant. It is for people with high-risk forms of acute leukemia or myelodysplastic syndrome who are not…

This study is testing whether adding an oral medication called azacitidine to standard supportive care can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older. Participants are in remission after initial chemotherapy. The goal is to see if…

This study allows patients already receiving venetoclax in other trials to continue treatment if they are benefiting and tolerating it well. The main goal is to collect long-term safety information by tracking any side effects. It includes about 165 patients with various blood ca…

This study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …

This study is testing whether two oral drugs, venetoclax and ASTX727, can help control acute myeloid leukemia (AML). It is for adults whose AML has come back or hasn't responded to prior treatment, or for older, newly diagnosed patients who cannot tolerate strong chemotherapy. Th…

This study aims to find out which of two chemotherapy combinations works better to prepare patients for a donor stem cell transplant. The transplant is a treatment for certain aggressive blood cancers. Researchers are comparing the drugs treosulfan and clofarabine to see which on…

This study allows a small group of patients with acute myeloid leukemia (AML) to continue receiving a generic oral version of the drug azacitidine after they finished a previous trial. The main goal is to monitor the safety and side effects of the drug when taken for a longer per…

This large, late-stage trial is testing whether adding the drugs bortezomib or sorafenib to standard chemotherapy can better control a fast-growing blood cancer called acute myeloid leukemia (AML) in children and young adults. It focuses on patients with a specific high-risk gene…

This study is testing a specific type of stem cell transplant for patients with various blood cancers. It uses stem cells from a partially matched family donor instead of bone marrow. The main goals are to see how well patients survive and recover, and to learn how the immune sys…

This study is testing whether adding a precise, targeted form of radiation to the standard pre-transplant drug regimen can improve outcomes for adults with high-risk forms of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to better prepare the body t…

This study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer ce…

This study aims to find out which type of donor leads to better outcomes for children and young adults receiving a stem cell transplant for serious blood cancers like leukemia. It directly compares transplants from a partially matched family member to those from a fully matched u…

This study is testing whether adding a drug called venetoclax to the standard chemotherapy given before a donor stem cell transplant works better for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to better prepare the body to accept the…

This study is testing a new, more targeted form of radiation as a preparatory step before a stem cell transplant. It is for patients with certain types of leukemia or myelodysplastic syndrome who need a transplant but do not have a fully matched donor. The goal is to see if this …

This early-stage study aims to find a safe dose for a new combination of three drugs (navitoclax, venetoclax, and decitabine) to treat aggressive forms of blood and bone marrow cancers. It will enroll about 36 adults with specific high-risk conditions like acute myeloid leukemia …

This early-stage study is testing a new therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or persists after standard treatment, including a stem cell transplant. Researchers take immune cells (T cells) from the patient's orig…

This study is testing if adding a new drug called veliparib to a standard two-drug chemotherapy works better for people with advanced blood cancers that have spread and are hard to treat. It will compare the two-drug combo with the three-drug combo in about 25 participants to see…

This study is testing if giving a special 'priming' drug for five days before standard chemotherapy helps children and young adults with acute myeloid leukemia (AML). The goal is to see if this approach is safe and if it makes the chemotherapy more effective at controlling the ca…

This is the first study in people testing a new oral drug called BMF-500 for adults with acute myeloid leukemia (AML), a type of blood cancer. The main goals are to find a safe dose and see how the body handles the drug. The study will also look for early signs that the drug migh…

This study is testing whether adding a drug called venetoclax to standard chemotherapy is safe and effective for children and young adults with newly diagnosed acute myeloid leukemia (AML). It will involve about 70 participants under 22 years old. The main goals are to see if the…

This early-stage trial aimed to test the safety of a new bone marrow transplant method for adults with leukemia and related blood cancers. It planned to use frozen bone marrow tissue from deceased, partially matched donors, combined with specific medications to prevent complicati…

This study is testing if a new pill form of the cancer drug cladribine works similarly to the standard version given through an IV. It involves 40 adults with specific types of leukemia. The main goal is to find the right pill dose that delivers the same amount of drug into the b…

This early-stage study is testing whether immune cells from healthy donors, given along with two other drugs, are safe for people with advanced colorectal, stomach, or hard-to-treat blood cancers. The goal is to see if this combination helps the donor immune cells last longer in …

This study is testing a new type of cell therapy for patients with blood cancers or bone marrow diseases who need a stem cell transplant from a partially matched family donor. The goal is to see if adding specially treated immune cells, called 'veto cells,' can help the donor's c…

This early-stage study is testing a new oral drug called navtemadlin (KRT-232) in combination with standard chemotherapy for adults newly diagnosed with a fast-growing blood cancer called acute myeloid leukemia (AML). The main goals are to find the safest and most effective dose …

This study is testing whether a combination of pills (ASTX727 and venetoclax) is as safe and effective as standard intravenous chemotherapy for younger adults with a high-risk type of acute myeloid leukemia (AML). The goal is to control the cancer and improve survival. The trial …

This early-stage study is testing a new type of cellular therapy for adults with acute myeloid leukemia or a related blood cancer that has come back or not responded to standard treatments. Doctors collect a patient's or donor's immune cells, genetically modify them in a lab to b…

This program provided early access to an investigational drug called ABBV-787 for people with acute myeloid leukemia before it received full regulatory approval. It was designed for eligible patients who had no other suitable treatment options and could not join ongoing clinical …

This study tests whether taking a daily pill called enasidenib can help prevent acute myeloid leukemia (AML) from coming back after a patient receives a stem cell transplant from a donor. The pill is designed to block a specific enzyme that helps cancer cells grow. The trial invo…

This early-stage study is testing a new three-drug combination for adults newly diagnosed with a serious blood cancer called acute myeloid leukemia (AML). The goal is to find a safe and effective dose. One drug is a targeted radioactive therapy designed to seek out and destroy ca…

This study is testing whether adding a drug called decitabine before standard chemotherapy helps treat acute myeloid leukemia (AML) more effectively. The goal is to see if decitabine can 'prime' or sensitize the cancer cells, making them easier for the chemotherapy drugs to kill.…

This study is testing whether tracking specific cancer-related genetic mutations in patients' blood can help doctors better predict who is at high risk of their leukemia returning. Researchers are following 107 adults with acute myeloid leukemia (AML) who are in remission after i…

This early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to tre…

This study is testing whether the immunotherapy drug nivolumab can help keep acute myeloid leukemia (AML) from coming back after successful chemotherapy. It will compare giving nivolumab as a long-term maintenance treatment against standard observation in 82 adults who are in rem…

This study is for adults with acute myeloid leukemia (AML) who have achieved a second remission after their cancer returned. It compares a new immunotherapy called Galinpepimut-S (GPS) against the doctor's choice of standard available treatments. The main goal is to see if GPS he…

This study is testing a new blood test called AlloHeme to see if it can predict when leukemia or a related blood cancer might return after a patient receives a bone marrow transplant. Researchers will track over 300 patients for two years, collecting regular blood and bone marrow…

This study is testing a special type of imaging scan (called FLT PET/CT) to see if it can accurately measure how well a patient's acute myeloid leukemia (AML) is responding to initial chemotherapy. The goal is to see if this scan, which tracks rapidly dividing cells, can provide …

This study is testing a vaccine designed to prevent cytomegalovirus (CMV) infection in adults with blood cancers who are receiving a half-matched stem cell transplant. CMV is a common virus that can become life-threatening when the immune system is weakened after transplant. The …

This study is testing whether an online coaching program for parents can help children who have survived leukemia or lymphoma do better in school. Many kids face learning and memory challenges after cancer treatment. Researchers are comparing this special website and video coachi…

This study tests whether a special parenting skills program helps Latino children who have survived leukemia or lymphoma do better in school. Researchers are comparing an intensive 8-session training for parents against a standard single-session meeting to see which improves chil…

This study is testing whether a type of talk therapy, delivered over the phone, can help patients with acute myeloid leukemia (AML) or lymphoma manage severe, long-lasting cancer-related fatigue. The therapy focuses on teaching patients skills to change unhelpful thoughts and beh…

This study is testing whether adding a specialized palliative care team to standard cancer treatment improves the experience for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The palliative care team focuses on managing pain, fatigue, anxiety, and …

This study aims to understand and track the long-term health problems that can develop in cancer survivors after their initial treatment is successful. It follows 500 adults who have finished treatment for certain cancers (like breast cancer, lymphoma, and leukemia) and are in re…

This study is testing whether advanced imaging scans (PET/MR, PET/CT, and whole-body MRI) can detect leukemia that has spread outside the bone marrow in newly diagnosed acute myeloid leukemia patients. Researchers want to see how often this hidden leukemia occurs and whether find…

This study aims to understand how muscle strength and body composition affect recovery and long-term health in people with blood cancers who receive a stem cell transplant. Researchers will observe 144 patients to see if their muscle health at the time of transplant can predict c…

This study aims to understand why people who survive a blood cancer transplant have a higher risk of heart disease. Researchers will closely monitor 350 adult patients' heart, lung, and muscle function before their transplant and for two years after. The goal is to learn how thes…

This study aims to understand how different treatments affect quality of life for older adults with acute myeloid leukemia (AML). Researchers are comparing quality of life between patients receiving intensive versus less intensive chemotherapy. The goal is to create a decision-ma…

This study aims to understand how a protein called adrenomedullin helps leukemia cells survive and grow in the bone marrow. Researchers will collect blood and bone marrow samples from 72 adults newly diagnosed with acute myeloid leukemia (AML). They will study how this protein in…

This study aims to see if testing cancer cells in a lab dish can predict which chemotherapy drugs will work best for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers will collect blood samples from 80 adults before and after they start st…

This study aims to understand how the body's immune system responds to leukemia tumors after they receive standard low-dose radiation treatment. Researchers will take small tissue samples and blood from about 10 adult patients with a type of blood cancer called acute myeloid leuk…

This study aims to find out how common a specific enzyme problem is in people with certain blood cancers and unexplained anemia. Researchers will take one blood sample from about 100 participants who have conditions like myelodysplastic syndrome (MDS) or other related disorders. …